Rociverine for nocturia in the elderly: medium-term controlled clinical trial.
Forty patients, aged 51 to 79 years, with nocturia due to bladder instability, resorption of postural edema, or senile decay, were treated with rociverine or flavoxate to test the possibility of reducing or eliminating nocturnal voidings. After a two-day observation period, each patient received either 20 mg of rociverine or 200 mg of flavoxate in a single dose at 8 PM. The following were assessed before the trial and after 14 and 28 days of treatment: number of night voidings, interval between drug administration and first voiding, volume of first voiding, volume of urine voided during the night, volume of morning urine, and total volume of urine passed between 8 PM and 8 AM. Routine laboratory tests performed before and after the trial showed both drugs to be well tolerated. The results of the trial show that rociverine reduced the number of night voidings significantly more (P less than 0.05) than did flavoxate.
D000368:Aged; D001643:Bridged Bicyclo Compounds / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003509:Cyclohexanecarboxylic Acids; D004341:Drug Evaluation; D004775:Enuresis / Q000188:drug therapy*; D005260:Female; D005419:Flavonoids / Q000627:therapeutic use*; D005422:Flavoxate / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation
D001643:Bridged Bicyclo Compounds; D001952:Bridged-Ring Compounds; D003509:Cyclohexanecarboxylic Acids; D005419:Flavonoids; D005422:Flavoxate; C021082:rociverine